Other equities research analysts have also recently issued research reports about the company. CIBC lowered their price target on Rocky Mountain Dealerships from C$10.50 to C$10.00 in a report on Thursday, May 2nd. Oppenheimer lowered their price target on Littelfuse from $215.00 to $210.00 and set an outperform rating on the stock in a report on Thursday, May 2nd. Zacks Investment Research upgraded DLH from a sell rating to a hold rating in a report on Tuesday, July 9th. Royal Bank of Canada restated an outperform rating on shares of in a report on Tuesday, June 25th. Finally, SunTrust Banks upped their price target on Accenture to $180.00 and gave the stock a hold rating in a report on Friday, March 29th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $22.17.
NASDAQ ATNX opened at $19.98 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.85 and a current ratio of 2.22. The stock’s 50 day simple moving average is $17.25. Athenex has a 12-month low of $9.38 and a 12-month high of $21.11.
In related news, Director Stephanie A. Davis bought 10,000 shares of Athenex stock in a transaction that occurred on Wednesday, June 26th. The shares were purchased at an average price of $18.00 per share, with a total value of $180,000.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $180,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Life Sciences Maste Perceptive bought 130,000 shares of Athenex stock in a transaction that occurred on Monday, June 17th. The stock was bought at an average cost of $17.94 per share, for a total transaction of $2,332,200.00. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 318,210 shares of company stock worth $5,111,581. Insiders own 18.80% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the stock. Perceptive Advisors LLC lifted its stake in Athenex by 77.6% in the 4th quarter. Perceptive Advisors LLC now owns 5,096,022 shares of the company’s stock valued at $32,550,000 after buying an additional 2,226,494 shares in the last quarter. BlackRock Inc. lifted its stake in Athenex by 0.9% in the 4th quarter. BlackRock Inc. now owns 3,616,333 shares of the company’s stock valued at $45,892,000 after buying an additional 33,755 shares in the last quarter. Geode Capital Management LLC lifted its stake in Athenex by 7.7% in the 4th quarter. Geode Capital Management LLC now owns 489,666 shares of the company’s stock valued at $6,213,000 after buying an additional 35,061 shares in the last quarter. Diag Capital Management LP purchased a new stake in Athenex in the 4th quarter valued at approximately $5,445,000. Finally, Emory University purchased a new stake in Athenex in the 1st quarter valued at approximately $2,312,000. 31.21% of the stock is currently owned by hedge funds and other institutional investors.
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
Read More: Return on Investment (ROI)
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.